STOCK TITAN
  1. Home
  2. News
  3. ATRC

Atricure - ATRC STOCK NEWS

Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.

AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.

The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.

AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.

Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.

For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.

News

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) has announced the launch of the cryoSPHERE+ cryoablation probe, aimed at post-operative pain management. The new device reduces freeze times by 25% compared to the previous model, enhancing patient care and procedural efficiency. With FDA clearance for pain management in adult and adolescent patients, the cryoSPHERE+ leverages innovative technology to improve outcomes and streamline procedures. The product is currently in a launch phase in the US, with a full rollout expected by the end of the second quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
News

AtriCure to Announce First Quarter 2024 Financial Results

Rhea-AI Summary
AtriCure, Inc. (ATRC) will release its first quarter 2024 financial results on May 1, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. An audio webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
earnings
-
News

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
AtriCure, Inc. (ATRC) will be participating in the 23rd Annual Needham Virtual Healthcare Conference with a fireside chat on April 9, 2024, at 1:30 p.m. EST. The company is known for its innovative surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. Interested parties can access the live webcast on the company's investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
conferences
News

AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) reported strong financial results for the fourth quarter and full year 2023, with worldwide revenue reaching $106.5 million in Q4 and $399.2 million for the full year. The company saw a 21.0% year-over-year increase in Q4 revenue and a 20.8% increase for the full year. Despite a net loss of $30.4 million for 2023, AtriCure achieved positive adjusted EBITDA of $19.4 million. The company treated over one million patients to date, showing significant growth and market penetration. AtriCure projects revenue growth of 15% to 17% for 2024, with adjusted EBITDA expected to increase by 34% to 49% over 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
earnings
-
News

AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference

Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) announced the release of its fourth quarter and full year 2023 financial results on February 15, 2024. The company will host an audio webcast to discuss the results and will also participate in investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
earnings
-
News

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024

Rhea-AI Summary
AtriCure, a leading innovator in surgical treatments for atrial fibrillation, announced preliminary financial results for Q4 2023 and full year 2023. The company expects a 21% growth in revenue for Q4 2023, with U.S. revenue at $88.7 million and international revenue at $17.8 million. Full year 2023 revenue is expected to be $399.2 million, reflecting a 21% growth over 2022. The company also provided 2024 financial guidance, projecting revenue of $459 million to $466 million, and positive adjusted EBITDA of $26 million to $29 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
earnings
News

AtriCure Appoints Shlomi Nachman to the Board of Directors

Rhea-AI Summary
AtriCure, a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, has appointed Shlomi Nachman, a highly experienced professional in the medical device industry, to its Board of Directors. Mr. Nachman's extensive experience and leadership roles in the medical device industry, particularly in the Afib treatment market, make him a valuable addition to AtriCure's board. His appointment is expected to contribute to the company's accelerating growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
management
-
News

AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) to participate in 42nd Annual J.P. Morgan Healthcare Conference, presenting on January 10, 2024, at 7:30 a.m. Pacific Standard Time. Interested parties can access a live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
conferences
-
News

AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) to participate in Piper Sandler 35th Annual Healthcare Conference. Management to have fireside chat on November 29, 2023, at 9:30 a.m. EST. Live webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
conferences
News

AtriCure Releases 2023 ESG Report

Rhea-AI Summary
AtriCure, Inc. (Nasdaq: ATRC) Announces Publication of 2023 ESG Report, Highlighting Corporate Responsibility and Sustainability Initiatives. The report details key accomplishments, including recognition for Diversity, Equity & Inclusion, launching clinical trials, cultivating talent, enhancing employee learning, strengthening relationships across the supply chain, and expanding education to new audiences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
none

FAQ

What is the current stock price of Atricure (ATRC)?

The current stock price of Atricure (ATRC) is $38.74 as of February 28, 2025.

What is the market cap of Atricure (ATRC)?

The market cap of Atricure (ATRC) is approximately 1.9B.

What does AtriCure, Inc. specialize in?

AtriCure, Inc. specializes in innovative technologies for the treatment of atrial fibrillation (Afib) and related conditions.

What is the Isolator® Synergy™ Ablation System?

The Isolator® Synergy™ Ablation System is the first and only FDA-approved medical device for the treatment of persistent Afib.

What is AtriClip?

AtriClip is a widely sold Left Atrial Appendage (LAA) management device with over 100,000 units implanted globally.

How does AtriCure distribute its products?

AtriCure distributes its products through a combination of a direct sales force and a network of distributors.

What types of products does AtriCure offer?

AtriCure offers products for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, as well as minimally invasive ablation devices and access tools.

Where does AtriCure generate most of its revenue?

AtriCure generates the majority of its revenue from the United States.

Are AtriCure’s products used internationally?

Yes, electrophysiologists and cardiothoracic surgeons around the globe use AtriCure’s technologies.

What makes AtriCure's products unique?

AtriCure's products are unique due to their FDA approval and widespread use in treating persistent Afib and LAA management.

Where can I find more information about AtriCure?

You can find more information on AtriCure's official website at AtriCure.com or follow them on Twitter @AtriCure.

What are AtriCure’s latest achievements?

AtriCure's latest achievements include FDA approval for its Isolator® Synergy™ Ablation System and the widespread adoption of its AtriClip device.
Stock ATRC logo
Atricure

Nasdaq:ATRC

ATRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ATRC Stock Data

1.87B
47.21M
3.43%
104.42%
3.02%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MASON